Ipca Laboratories Dividends and Buybacks
Dividend criteria checks 4/6
Ipca Laboratories is a dividend paying company with a current yield of 0.25% that is well covered by earnings.
Key information
0.3%
Dividend yield
n/a
Buyback Yield
Total Shareholder Yield | n/a |
Future Dividend Yield | 0.4% |
Dividend Growth | 2.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | ₹4.000 |
Payout ratio | 15% |
Recent dividend and buyback updates
Recent updates
Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
Dec 20Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00
Nov 17Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)
Sep 10Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
Jun 07Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
May 24Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
Feb 07Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Aug 20Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Feb 28Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Sep 20Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)
Aug 31Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Jun 22Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)
May 28Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Mar 15These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well
Sep 20Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Aug 09Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Jun 08How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?
Mar 26Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?
Mar 13Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently
Feb 28Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 23Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?
Feb 11Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?
Jan 30Stability and Growth of Payments
Fetching dividends data
Stable Dividend: IPCALAB's dividend payments have been volatile in the past 10 years.
Growing Dividend: IPCALAB's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
Ipca Laboratories Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (IPCALAB) | 0.3% |
Market Bottom 25% (IN) | 0.2% |
Market Top 25% (IN) | 1.1% |
Industry Average (Pharmaceuticals) | 0.7% |
Analyst forecast (IPCALAB) (up to 3 years) | 0.4% |
Notable Dividend: IPCALAB's dividend (0.25%) is higher than the bottom 25% of dividend payers in the Indian market (0.24%).
High Dividend: IPCALAB's dividend (0.25%) is low compared to the top 25% of dividend payers in the Indian market (1.11%).
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (15.4%), IPCALAB's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (11.3%), IPCALAB's dividend payments are thoroughly covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 13:03 |
End of Day Share Price | 2024/12/26 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ipca Laboratories Limited is covered by 46 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Aditya Khemka | Ambit Capital |
null null | Anand Rathi Shares and Stock Brokers Limited |
Sanjeev Chiniwar | Anand Rathi Shares and Stock Brokers Limited |